The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury

Shingo Yoshizaki, Kazuya Yokota, Kensuke Kubota, Takeyuki Saito, Masatake Tanaka, Dai jiro Konno, Takeshi Maeda, Yoshihiro Matsumoto, Yasuharu Nakashima, Seiji Okada

Research output: Contribution to journalArticle

Abstract

Study design: Experimental study with mice. Objectives: Spasticity is a common complication after spinal cord injury (SCI) and has detrimental aspects, such as persistent pain and involuntary muscle spasms. This study aimed to assess the influence of antispastic therapy on locomotor function after SCI. Setting: University-based laboratory in Fukuoka, Japan. Methods: A mouse model of spasticity was developed by producing incomplete SCI at the 9th thoracic level. At 8 weeks after SCI, an antispastic drug, baclofen, was intraperitoneally administered to six injured and two sham-operated mice. The severity of spasticity was evaluated by the modified Ashworth scoring (MAS) system, and locomotor function was evaluated by the Basso–Beattie–Bresnahan (BBB) scale/Basso mouse score (BMS). Results: The administration of baclofen significantly improved spasticity in the SCI mice and the mean MAS decreased to from 6.2 to 2.8. However, at the same time, it significantly exacerbated the locomotor dysfunction of the SCI mice and the mean BMS decreased from 4.7 to 2.3. The time-course of the changes in locomotor function coincided with the time-course of the spasticity score. We also confirmed that the administration of baclofen was not associated with any changes in either locomotor function or spasticity of the sham-operated control mice. Conclusions: Our results suggest that spasticity has a certain beneficial effect on ambulation ability. It is important to note that antispastic treatments may be associated with a risk of impairing the preserved function of chronic SCI patients.

Original languageEnglish
JournalSpinal Cord
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Aptitude
Spinal Cord Injuries
Baclofen
Spasm
Walking
Smooth Muscle
Japan
Research Design
Thorax
Pain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury. / Yoshizaki, Shingo; Yokota, Kazuya; Kubota, Kensuke; Saito, Takeyuki; Tanaka, Masatake; Konno, Dai jiro; Maeda, Takeshi; Matsumoto, Yoshihiro; Nakashima, Yasuharu; Okada, Seiji.

In: Spinal Cord, 01.01.2019.

Research output: Contribution to journalArticle

Yoshizaki, Shingo ; Yokota, Kazuya ; Kubota, Kensuke ; Saito, Takeyuki ; Tanaka, Masatake ; Konno, Dai jiro ; Maeda, Takeshi ; Matsumoto, Yoshihiro ; Nakashima, Yasuharu ; Okada, Seiji. / The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury. In: Spinal Cord. 2019.
@article{e34d459deebf499ea85f83f087b5f459,
title = "The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury",
abstract = "Study design: Experimental study with mice. Objectives: Spasticity is a common complication after spinal cord injury (SCI) and has detrimental aspects, such as persistent pain and involuntary muscle spasms. This study aimed to assess the influence of antispastic therapy on locomotor function after SCI. Setting: University-based laboratory in Fukuoka, Japan. Methods: A mouse model of spasticity was developed by producing incomplete SCI at the 9th thoracic level. At 8 weeks after SCI, an antispastic drug, baclofen, was intraperitoneally administered to six injured and two sham-operated mice. The severity of spasticity was evaluated by the modified Ashworth scoring (MAS) system, and locomotor function was evaluated by the Basso–Beattie–Bresnahan (BBB) scale/Basso mouse score (BMS). Results: The administration of baclofen significantly improved spasticity in the SCI mice and the mean MAS decreased to from 6.2 to 2.8. However, at the same time, it significantly exacerbated the locomotor dysfunction of the SCI mice and the mean BMS decreased from 4.7 to 2.3. The time-course of the changes in locomotor function coincided with the time-course of the spasticity score. We also confirmed that the administration of baclofen was not associated with any changes in either locomotor function or spasticity of the sham-operated control mice. Conclusions: Our results suggest that spasticity has a certain beneficial effect on ambulation ability. It is important to note that antispastic treatments may be associated with a risk of impairing the preserved function of chronic SCI patients.",
author = "Shingo Yoshizaki and Kazuya Yokota and Kensuke Kubota and Takeyuki Saito and Masatake Tanaka and Konno, {Dai jiro} and Takeshi Maeda and Yoshihiro Matsumoto and Yasuharu Nakashima and Seiji Okada",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41393-019-0395-9",
language = "English",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury

AU - Yoshizaki, Shingo

AU - Yokota, Kazuya

AU - Kubota, Kensuke

AU - Saito, Takeyuki

AU - Tanaka, Masatake

AU - Konno, Dai jiro

AU - Maeda, Takeshi

AU - Matsumoto, Yoshihiro

AU - Nakashima, Yasuharu

AU - Okada, Seiji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Study design: Experimental study with mice. Objectives: Spasticity is a common complication after spinal cord injury (SCI) and has detrimental aspects, such as persistent pain and involuntary muscle spasms. This study aimed to assess the influence of antispastic therapy on locomotor function after SCI. Setting: University-based laboratory in Fukuoka, Japan. Methods: A mouse model of spasticity was developed by producing incomplete SCI at the 9th thoracic level. At 8 weeks after SCI, an antispastic drug, baclofen, was intraperitoneally administered to six injured and two sham-operated mice. The severity of spasticity was evaluated by the modified Ashworth scoring (MAS) system, and locomotor function was evaluated by the Basso–Beattie–Bresnahan (BBB) scale/Basso mouse score (BMS). Results: The administration of baclofen significantly improved spasticity in the SCI mice and the mean MAS decreased to from 6.2 to 2.8. However, at the same time, it significantly exacerbated the locomotor dysfunction of the SCI mice and the mean BMS decreased from 4.7 to 2.3. The time-course of the changes in locomotor function coincided with the time-course of the spasticity score. We also confirmed that the administration of baclofen was not associated with any changes in either locomotor function or spasticity of the sham-operated control mice. Conclusions: Our results suggest that spasticity has a certain beneficial effect on ambulation ability. It is important to note that antispastic treatments may be associated with a risk of impairing the preserved function of chronic SCI patients.

AB - Study design: Experimental study with mice. Objectives: Spasticity is a common complication after spinal cord injury (SCI) and has detrimental aspects, such as persistent pain and involuntary muscle spasms. This study aimed to assess the influence of antispastic therapy on locomotor function after SCI. Setting: University-based laboratory in Fukuoka, Japan. Methods: A mouse model of spasticity was developed by producing incomplete SCI at the 9th thoracic level. At 8 weeks after SCI, an antispastic drug, baclofen, was intraperitoneally administered to six injured and two sham-operated mice. The severity of spasticity was evaluated by the modified Ashworth scoring (MAS) system, and locomotor function was evaluated by the Basso–Beattie–Bresnahan (BBB) scale/Basso mouse score (BMS). Results: The administration of baclofen significantly improved spasticity in the SCI mice and the mean MAS decreased to from 6.2 to 2.8. However, at the same time, it significantly exacerbated the locomotor dysfunction of the SCI mice and the mean BMS decreased from 4.7 to 2.3. The time-course of the changes in locomotor function coincided with the time-course of the spasticity score. We also confirmed that the administration of baclofen was not associated with any changes in either locomotor function or spasticity of the sham-operated control mice. Conclusions: Our results suggest that spasticity has a certain beneficial effect on ambulation ability. It is important to note that antispastic treatments may be associated with a risk of impairing the preserved function of chronic SCI patients.

UR - http://www.scopus.com/inward/record.url?scp=85076398252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076398252&partnerID=8YFLogxK

U2 - 10.1038/s41393-019-0395-9

DO - 10.1038/s41393-019-0395-9

M3 - Article

C2 - 31822806

AN - SCOPUS:85076398252

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

ER -